Crossmark

‘Patients are left not knowing’: Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer—a qualitative study of patient experience

Crossref DOI link: https://doi.org/10.1007/s00520-026-10357-y

Published Online: 2026-02-05

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dolgilevica, Karina

Chapman, Bethany

Derakshan, Nazanin https://orcid.org/0000-0001-7780-4435
License Information

Text and Data Mining valid from 2026-02-05

Version of Record valid from 2026-02-05
More Information

Article History

Received: 1 May 2025

Accepted: 15 January 2026

First Online: 5 February 2026

Declarations

:

: The study was approved by the ethics committee of the School of Psychology and Clinical Language Sciences at the University of Reading (Reference number: 2023-021-ND) and carried out in accordance with the Helsinki Declaration.Informed consentAll participants gave informed consent prior to taking part in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below